Piper Sandler Reiterates Overweight Rating on Madrigal Pharmaceuticals (MDGL)

June 24, 2026 9:42 AM

Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $900.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found